PA
CGEM icon

Perceptive Advisors’s Cullinan Oncology CGEM Stock Holding History

Perceptive Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.77M Buy
+426,478
New +$6.33M 0.12% 86
2025
Q2 		– Sell
-80,100
Closed -$606K – 90
2025
Q1 		$606K Buy
+80,100
New +$769K 0.02% 80
2024
Q3 		– Sell
-749,916
Closed -$13.1M – 112
2024
Q2 		$13.1M Buy
+749,916
New +$16M 0.32% 63

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Perceptive Advisors's CGEM Position: Q2 2026 in Review

Perceptive Advisors opened a new position in Cullinan Oncology (CGEM) in Q2 2026: 426,478 shares worth $7.77M. The stake represents 0.12% of the portfolio and ranks #86 among its holdings. This is a return to the name: Perceptive Advisors previously reported a position in CGEM as recently as Q1 2025.

Perceptive Advisors first reported a position in CGEM in Q2 2024 and has held it in 3 quarters since. The position peaked at $13.1M in Q2 2024. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Perceptive Advisors held 426,478 shares of Cullinan Oncology worth $7.77M as of Q2 2026.
  • Cullinan Oncology was a new Perceptive Advisors position in Q2 2026.
  • Cullinan Oncology made up 0.12% of Perceptive Advisors's portfolio in Q2 2026, its #86 holding.
  • Perceptive Advisors first reported a position in Cullinan Oncology in Q2 2024 and has held it in 3 quarters since.
  • Perceptive Advisors's Cullinan Oncology position peaked at $13.1M in Q2 2024.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.